Propecia Research Today is a free monthly online journal that collates and summarizes the latest research about Propecia, including details on baldness, hair loss, side-effects, results.

Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study.

van Exel NJ, Koopmanschap MA, McDonnell J, Chapple CR, Berges R, Rutten FF,

Institute for Medical Technology Assessment (iMTA), Erasmus MC, Rotterdam, The Netherlands. n.vanExel@ErasmusMC.nl

OBJECTIVE: To determine the medical consumption and associated treatment costs of patients with LUTS suggestive of BPH. METHODS: A prospective, cross-sectional, observational survey in six European countries: France, Germany, Italy, Poland, Spain and the United Kingdom, with a one-year follow-up of incident and prevalent patients. RESULTS: Treatment costs were estimated for 5,057 patients with a mean age of 66 years and a mean IPSS score at inclusion of 11.5. In 30% of patients watchful waiting was the therapy of choice for the full follow-up period, 57% were prescribed alpha-lockers, 11% finasteride and 10% phytotherapy at any moment during the follow-up (including switches and combination of treatment). Surgery rate was 4.9%. Mean one-year treatment costs were 858 per patient, three quarters of which concerned medication costs. Multivariate regression analysis showed that medication choice, complications and undergoing surgery were associated with higher costs. CONCLUSIONS: Treatment costs for patients with LUTS suggestive of BPH were moderate and largely consisted of medication costs. Daily practice and associated costs varied considerably across the six countries.

Published 19 December 2005 in Eur Urol, 49(1): 92-102.
Full-text of this article is available online (may require subscription).

© 2004-2008 Propecia Research Today. All Rights Reserved.